MicroRNA 4641 (miR-4641)

MicroRNA 4641 (miR-4641, also known as hsa-mir-4641 or MIR4641) is a short, non-coding RNA molecule of 20-24 nucleotides that falls within the microRNA class[1]. MicroRNAs act as post-transcriptional regulators of gene expression, typically by causing the degradation of target messenger RNAs (mRNAs) or repressing their translation into proteins[1][5]. miR-4641 is transcribed from its gene locus as a primary transcript, which is sequentially processed by the Drosha and Dicer enzymes to yield the mature miRNA molecule[1][5]. In one reported pathway, miR-4641 plays a role in suppressing hepatocellular carcinoma growth and metastasis by targeting PCK1, a gene involved in gluconeogenesis[1]. Like other human microRNAs, miR-4641 likely fine-tunes a wide array of physiological and potentially pathological processes but its precise functions and direct therapeutic targeting remain under ongoing investigation[2][5]. miRNAs, as a class, regulate more than 30% of human gene sets, impacting various physiologic and pathologic processes, including major roles in cancer biology and cell fate determination[2][5]. While miR-4641 is not typically categorized as a classical therapeutic target (such as a receptor or enzyme), its gene regulatory effects can be harnessed indirectly for diagnosis or therapy, particularly in oncology research contexts[1]. There are currently no approved drugs known to specifically target miR-4641, nor recognized safety concerns uniquely associated with this microRNA based on available data[1].

Other names

hsa-mir-4641MIR4641miR-4641